Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients

INDIANAPOLIS, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study evaluating the safety and eff... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, Ankylosing Spondylitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news